Renagel is growing significantly around the world foundation in the United States, Europe, and Japan. With more than 1.2 million people around the globe undergoing need and the prospects are both substantial.

Genzyme is committed to serving patients all along the spectrum of renal disease. In early 2005, we initiated a clinical trial for sevelamer carbonate and will begin another for patients with chronic kidney disease (CKD). We believe that 600,000 to 700,000 of the approximately one million CKD patients in the United States will form the market for this product.